Prestige Consumer Healthcare Hits New 52-Week Low at $42.66

Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 42.66 as of May 14, 2026. This marks a significant decline for the small-cap company, which operates within the Pharmaceuticals & Biotechnology industry. Over the past year, Prestige Consumer Healthcare has experienced a performance drop of 30.08%, contrasting sharply with the S&P 500's gain of 27.3%. The company's financial metrics reveal a P/E ratio of 16.00, indicating a valuation that is in line with its peers. However, the lack of dividend yield and a debt-to-equity ratio of 0.54 suggest a cautious approach to financial leverage. The return on equity stands at 10.66%, while the price-to-book ratio is 1.71, reflecting a fair valuation relative to historical averages. Recent quarterly results have shown a decline in key performance indicators, with net sales hitting a low of USD 249.53 million and operating profit at USD 79.42 million. Despite a modest annual growth rate in net sales and operating profit of 3.13% and 3.08%, respectively, the overall performance has been below par, contributing to the stock's current position in the market.